Total Funding
81
36
Total FundingGrant raised
Growth Score
-8 pts
Heat Score
-18 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
87748
PharmNovo addresses the high unmet need of treatments for chronic pain, which affects up to 30% of the adult population in the USA & Europe.
- Per von Mentzer: Chief Executive Officer
- David Kendall: Chief Scientific Officer
About the Company
PharmNovo's goal is to develop novel Delta Opioid Receptor Agonists that are safe and effective for chronic pain treatment (DORAs). This is a very different target than traditional opioid drugs, which have caused an epidemic of addiction and toxicity.
The company addresses the significant unmet medical need for safe and effective chronic pain
treatments, which affects up to 30% of the adult population in the United States and Europe.
